Additional Information
| Product Name: | ONX-0914 (PR-957) |
|---|---|
| Also Known As: | ONX 0914; ONX0914; ONX-0914; PR-957; CAS#: 960374-59-8 |
| Catalog No.: | F1411 |
| Size: | 25 mg |
| Molecular Weight: | 580.7 Da |
| Species: | N/A |
| Source: | Synthetic |
| Stock: | Powder |
| Concentration: | N/A |
| Quality Assurance: | >98% by HPLC and NMR |
| Storage: | Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh. |
| PDF Data Sheet: | PDF Datasheet, MSDS |
| NCBI RefSeq: | N/A |
| Image(s): | No |
| Shipping Method: | Room temperature shipping |
| References: | 1. Muchamuel T, et al. (2009) Nat Med. 15(7):781-7. 2. Basler M, et al. (2010) J Immunol. 185(1):634-41. 3. Kalim KW, et al. (2012) J Immunol. 189(8):4182-93. |
Details
ONX-0914, also known as PR-957, is a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome. ONX-0914 selectively inhibits low-molecular mass polypeptide-7 (LMP7), the subunit specific for the immunoproteasome that catalyzes the chymotyrpsion-like activity, with an IC50 < 100 nM. Cell culture and animal studies have shown that ONX-0914 blocks the production of proinflammatory cytokines including interleukin-6 and 17, indicating that it has potential uses in the treatment of some autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and lupus.
Dose: 0.1-0.5 μM for in vitro or cell couture assays; intravenous or subcutaneous administration at 2-10 mg/Kg daily for 5-7 days for animal studies.
